Aurinia Pharmaceuticals Inc

AUPHNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
15.69 USD
↘ 0.03 (0.19%)AT CLOSE (03:59 PM EDT)
15.72
↗ 0.03 (0.16%)
POST MARKET (AS OF 06:03 PM EDT)
Post Market
AS OF 06:03 PM EDT
15.72
↗ 0.03 (0.16%)
🟢Market: OPEN

Aurinia Pharmaceuticals Inc (AUPH) is currently trading at $15.72. The stock presents a mixed profile: our models indicate a Strong Buy for underlying fundamentals, while technical indicators flash a Strong Sell. Notable factors include a robust Altman Z-Score, a strong Piotroski F-Score of 7/9, exceptional Return on Equity (51.1%) and a bullish Golden Cross on the moving averages. Valuation metrics place AUPH at a fair price relative to peers.

Technical & fundamental data as of Oct 6, 2026.

Open?$15.77
High?$15.82
Low?$15.47
Prev. Close?$15.72
Volume?698.7K
Avg. Volume?807.2K
VWAP?$15.67
Rel. Volume?0.87x
Bid / Ask
Bid?$13.41 × 100
Ask?$18.04 × 100
Spread?$4.63
Midpoint?$15.73
Valuation & Ratios
Market Cap?2.1B
Shares Out?133.1M
Float?103.0M
Float %?79.2%
P/E Ratio?6.66
P/B Ratio?3.40
EPS?$2.36
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Themes
Biotech - Drug Development›Immunology & AutoimmuneBiotech - Drug Development›Rare Disease Therapeutics
Employees
128
Market Cap
2.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.auriniapharma.com
Listed
2009-10-21
Address
#140, 14315 - 118 AVENUE
EDMONTON, A0 T5L 4S6
Phone: 250-744-2487
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookStrong Buy
Strong SellNeutralStrong Buy
F-Score?
88
Z-Score?
100
Momentum?
90
Short Sent.?
48
Piotroski F-Score?7/9Strong
Altman Z-Score?7.69Safe
Confidence?66%Moderate
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?8.33%Elevated
Short Interest?8.6M
Days to Cover?11.1
Free Float103.0M
Avg Daily Volume774.1K
Settlement Date2026-09-15
Financial Health
Current Ratio?5.42Strong
Quick Ratio?4.97Strong
Cash Ratio?1.80Strong
Debt/Equity?0.10Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
72/100
P/E?
Peers
100
S&P
97
6.7CHEAP▾
P/B?
Peers
100
S&P
50
3.40FAIR▾
P/S?
Peers
100
S&P
18
6.71FAIR▾
P/FCF?
Peers
100
S&P
83
12.0CHEAP▾
EV/EBITDA?
Peers
100
S&P
64
12.6FAIR▾
EV/Sales?
Peers
100
S&P
25
6.33HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
91
51.1%STRONG▾
ROA?
Peers
50
S&P
97
39.7%STRONG▾
Cash Flow & Enterprise
FCF?$175.1M
Enterprise Value?$2.0B
Fundamentals ratios updated end of day
MarketsMoversWatchlist